Effects of Atypical Versus Conventional Antipsychotics on the Prevalence of Tardive Dyskinesia

This study has been completed.
Sponsor:
Collaborator:
Yale University
Information provided by:
National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:
NCT00237835
First received: October 7, 2005
Last updated: February 22, 2006
Last verified: October 2005
  Purpose

This study will compare the effects of newer atypical antipsychotics with those of older conventional antipsychotics on the risk of tardive dyskinesia.


Condition
Tardive Dyskinesia

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Prevalence of Tardive Dyskinesia Among Patients Treated With Atypical Vs Conventional Antipsychotic

Further study details as provided by National Institute of Mental Health (NIMH):

Detailed Description:

We hypothesize that the newer atypical antipsychotics may not have lower risks of tardive dyskinesia compared to the older conventional antipsychotics.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients at the Connecticut Mental Health Center receving antipsychotics

Exclusion Criteria:

  • severe neurological disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00237835

Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Scott W Woods, MD Yale University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00237835     History of Changes
Other Study ID Numbers: R01 MH61008, DSIR AT-SP
Study First Received: October 7, 2005
Last Updated: February 22, 2006
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Dyskinesias
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on April 17, 2014